GoodRx Partners with Eli Lilly to Expand Employer Access to Zepbound
Summary
GoodRx Holdings announced a collaboration with Eli Lilly to expand employer-sponsored access to Zepbound Kwikpen, a highly sought-after GLP-1 medication. Under the program, self-insured employers can subsidize the $449 Lilly price for Zepbound via GoodRx's platform. This strategic partnership is a significant positive development for GoodRx, especially following its recent 2025 financial results which indicated declining core user metrics and a weaker 2026 outlook. Expanding into the high-demand GLP-1 market through employer plans could provide a material boost to GoodRx's user base and transaction revenue, offering a new growth vector for the company. Investors will be watching for details on adoption rates and the financial impact of this program.
At the time of this announcement, GDRX was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $784.5M. The 52-week trading range was $1.77 to $5.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.